Oct 29
Earnings call
Q2 2027 earnings call
Jaxampal Pharmaceuticals Ltd. reported organic growth of 9.3%, H1 EBITDA margin of 22.9% and cash and bank balance of 135 crores. It targets Rs. 500 crore by FI 2028 and Q3 revenue crossing 100 crores with consolidated EBITDA margin above 22%.